Analyst Price Targets — NUVB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 27, 2026 1:20 pm | — | Truist Financial | $13.00 | $5.66 | TheFly | Nuvation Bio price target raised to $13 from $11 at Truist |
| January 21, 2026 11:35 am | Leonid Timashev | RBC Capital | $12.00 | $6.01 | TheFly | Nuvation Bio price target raised to $12 from $9 at RBC Capital |
| January 12, 2026 1:51 pm | — | H.C. Wainwright | $17.00 | $6.52 | TheFly | Nuvation Bio price target lowered to $17 from $18 at H.C. Wainwright |
| January 7, 2026 5:45 am | Michael Yee | UBS | $10.00 | $8.49 | StreetInsider | UBS Starts Nuvation Bio Inc (NUVB) at Neutral |
| December 11, 2025 11:25 am | — | H.C. Wainwright | $18.00 | $7.89 | TheFly | Nuvation Bio price target raised to $18 from $10 at H.C. Wainwright |
| December 1, 2025 11:34 am | Robert Burns | H.C. Wainwright | $10.00 | $8.04 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Nuvation Bio Inc (NUVB) |
| November 24, 2025 12:21 pm | — | Truist Financial | $11.00 | $6.99 | TheFly | Nuvation Bio initiated with a Buy at Truist |
| November 20, 2025 11:20 am | — | JMP Securities | $10.00 | $7.29 | TheFly | Nuvation Bio price target raised to $10 from $8 at Citizens JMP |
| November 4, 2025 10:45 am | — | JMP Securities | $8.00 | $5.17 | TheFly | Nuvation Bio price target raised to $8 from $6 at Citizens JMP |
| April 23, 2025 9:28 am | Silvan Tuerkcan | JMP Securities | $6.00 | $2.08 | TheFly | Nuvation Bio initiated with an Outperform at Citizens JMP |
Latest News for NUVB
SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Nuvation Bio Inc. (NYSE: NUVB). The investigation focuses on whether Nuvation Bio and its executive officers complied with federal securities laws.
Knoll Capital Management added 473,591 shares of Nuvation Bio in the fourth quarter; the estimated trade size was $2.93 million. Meanwhile, the quarter-end position value increased by $7.88 million, reflecting both additional shares and price appreciation.
Nuvation Bio Inc. (NUVB) Q4 2025 Earnings Call Transcript
Nuvation Bio Inc. (NUVB) came out with a quarterly loss of $0.11 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.15 per share a year ago.
Successfully started 216 patients on IBTROZI ® (taletrectinib) in the fourth quarter of 2025, for a total of 432 new patient starts since launch in the second half of June 2025 Entered into exclusive licensing and collaboration agreement with Eisai on January 11, 2026, for taletrectinib in Europe and additional countries outside U.S., China and Japan Published positive Phase 2 study results for safusidenib…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NUVB.
U.S. House Trading
No House trades found for NUVB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.